Moonlight AI AG Raises $3.3M Seed Round
Share this article
Moonlight AI AG, a Swiss startup building image analysis software for clinical-grade diagnostics, has closed a $3.3 million USD Seed round. The investment was co-led by Lotus One Investment (Singapore), VP Venture Partners (Switzerland), and MEDIN Fund (Tunisia), with participation from N&V Capital (Liechtenstein) and existing investor QAI Ventures (Switzerland).
Turning routine slide images into actionable genomic insights
While precision oncology relies on access to genomic data, Next-Generation Sequencing (NGS) remains a bottleneck due to high costs and long turnaround times. Moonlight AI solves this by using computer vision to detect genomic biomarkers and complex disease signatures directly from routine imaging of blood and cytology smears.
“Our technology enables labs to generate actionable, immediate results from slides they already use in their core workflows,” said Christian Ruiz, CEO and co-founder of Moonlight AI. “By removing the need for expensive hardware or manual processes, we are empowering labs to scale their diagnostic capacity and deliver faster results to patients.”
Scaling The World’s First Cytopathology Dataset Spanning Imaging and Genomics
A primary focus of Moonlight AI’s Seed round is the expansion of their proprietary data library, the first to link whole slide imaging of cytopathology samples with high-quality genomic data. According to CTO and co-founder Nicole H. Romano, “By collaborating with an international consortium of clinical partners, we are curating a dataset that is poised to support model robustness across real-world laboratory settings and patient populations.”
The funding round brings together an international syndicate of investors from Europe, North Africa, and Asia:
Alexandra Beckstein, QAI Ventures: “Having backed Moonlight AI early, it’s encouraging to see the team reach this milestone. We look forward to seeing their continued progress toward clinical adoption and scale.”
Asmita Dwivedi, Lotus One Investment Pte. Ltd.: “We invested with strong conviction in the founders, who combine deep clinical and scientific expertise with a clear sense of purpose. They are addressing a critical gap in disease detection, with the potential to make high-quality diagnostics more affordable and widely available.”
Ruth Ketley, VP Venture Partners: “Moonlight AI is addressing a real bottleneck in clinical diagnostics. The team has the potential to meaningfully improve laboratory efficiency and patient care.”
Ghazi Ben Othman, MEDIN Fund: “We are excited to be backing a world class scientific team that is developing bleeding-edge technology to bring relief to millions of cancer patients.”
Moonlight AI will use the funding to expand its team and further develop diagnostic solutions in myelodysplastic syndrome (MDS), non-small cell lung cancer, and chronic lymphocytic leukemia (CLL), while accelerating the path to commercialization and regulatory approval. The funding coincides with Moonlight AI’s transition into a Swiss Stock Corporation (Aktiengesellschaft), positioning the company for international expansion and commercial rollout.
According to Dr. Stefan Habringer, Chief Medical Officer and co-founder of Moonlight AI, “The success of AI‑based diagnostics depends fundamentally on the quality and diversity of clinical data. We are therefore opening our consortium to additional hospitals and laboratories interested in shaping the next generation of diagnostics.”
About Moonlight AI AG
Moonlight AI, based in Courroux (Jura) is a Swiss Stock Corporation specialized in AI-driven diagnostics. By converting medical images into actionable insights, Moonlight AI empowers hematologists and pathologists to make faster, more accurate treatment decisions for cancer patients worldwide.
➡️ Source: Moonlight AI AG | 📸 ©Moonlight AI AG. From L to R : Christian Ruiz, CEO, Nicole H. Romano, CTO and co-founder and Stefan Habringer, Chief Medical Officer and co-founder.